# BPC-157 TB-500 References: The Cited Record | Wolverine Order

> BPC-157 TB-500 references: the peer-reviewed studies, reviews, and FDA sources behind every claim on this site, with DOIs, PubMed links, and the FDA compounding pages.

The full reference list behind this site — the constituent studies, the recent reviews, and the FDA compounding pages that govern access. Each entry links to the primary source.

## How to read this list

This is the complete reference set for the BPC-157 TB-500 material on this site. Findings tagged to BPC-157 draw on entries [1] through [5] and the recent reviews [9] through [11]; findings tagged to TB-500 draw on the Thymosin Beta-4 structural and review literature [6] through [8]. The regulatory section draws on the FDA compounding pages [12] through [14] and the access-pathway framework [21], which are the only sources used for any regulatory or access fact on this site.

A standing caveat applies to the TB-500 entries: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the Ac-LKKTETQ heptapeptide actually sold under that name [8]. We have kept that distinction in the body copy throughout. Full citations, with DOIs and PubMed identifiers where available, are listed below.

## References

[1] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[2] Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. https://pubmed.ncbi.nlm.nih.gov/33051481/
[3] Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-19077. https://pubmed.ncbi.nlm.nih.gov/25415472/
[4] Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110:774-780. https://pubmed.ncbi.nlm.nih.gov/21030672/
[5] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[6] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[7] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[8] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[9] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[10] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[11] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[12] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (list entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; entries effective September 29, 2023). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[13] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; 503A bulks-list framework). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[14] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157 and TB-500 among substances being considered for inclusion on the 503A Bulks List). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[21] U.S. Food and Drug Administration. Human Drug Compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (lawful compounded-access pathway: licensed-prescriber evaluation, patient-specific prescription, 503A pharmacy or 503B outsourcing facility, with ingredient-eligibility requirements). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

---

A soft pastel reading-room for the BPC-157 and TB-500 record — each peptide read kindly against its own studies, the missing blend trial left plainly unfilled, and the FDA 503A status set out gently; nothing is dispensed and nothing is sold here.